0MR5 Stock Chart & Stats
kr166.60
kr0.60(0.43%)
At close: 4:00 PM EDT
kr166.60
kr0.60(0.43%)
Day’s Range― - ―
52-Week Rangekr118.80 - kr188.40
Previous CloseN/A
Volume55.00
Average Volume (3M)1.19K
Market Cap
kr3.97B
Enterprise Valuekr3.13K
Total Cash (Recent Filing)kr172.19M
Total Debt (Recent Filing)kr52.27M
Price to Earnings (P/E)30.4
Beta1.25
Next Earnings
Oct 29, 2026EPS Estimate
1.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding23,851,547
10 Day Avg. Volume874
30 Day Avg. Volume1,194
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr150.00Price Target Upside-9.96% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)5.93
Revenue Forecast (FY)kr783.83M
Bulls Say, Bears Say
Bulls Say
Sustained High ProfitabilityConsistently strong gross and EBIT margins indicate differentiated medical-technology products and pricing power. This profitability supports continued investment in software, applications and R&D while providing resilience if demand softens.
Very Conservative Balance SheetMinimal leverage reduces financial risk and preserves flexibility for product development, commercial expansion or acquisitions. Growing equity and solid returns on equity further support the company’s capacity to fund its strategy internally.
Americas Growth And Product ExpansionStrong Americas execution, instrument refreshes and tender wins demonstrate market traction. The Bone Marrow application and planned U.S. launch could broaden the addressable market and add recurring software, reagent and service revenue.
Bears Say
Recent Revenue And Margin DecelerationThe TTM slowdown shows that recent growth has not been uniformly sustained after a strong 2025. Lower revenue and margins could limit operating leverage and make future performance more dependent on new applications and regional recovery.
Volatile Free Cash FlowHealthy operating cash flow supports earnings quality, but uneven free cash flow reduces predictability. Working-capital needs, inventory and receivables can absorb cash as the business grows, constraining internally funded investment or distributions.
APAC And China Market WeaknessWeakness in APAC, particularly China, highlights geographic execution and demand risk. Prolonged regional pressure could offset gains elsewhere, slow installed-base expansion and reduce the contribution from instruments, software and recurring reagents.
CellaVision AB News
0MR5 FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest share price was kr118.80 and its highest was kr188.40 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is kr3.97B.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Oct 29, 2026 which is in 57 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Jul 17, 2026. The company reported kr1.37 earnings per share for the quarter, beating the consensus estimate of kr1.339 by kr0.031.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB does not currently pay dividends.
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 1.45.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of kr1.37 in its last earnings report, beating expectations of kr1.339. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in GB:0MR5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
0MR5 Company Deck
0MR5 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and commercial picture: solid top-line growth (4.5% YoY; ~6% organic), record Americas performance (+≈59% in Americas sales), healthy margins (70% gross margin; 27% EBITDA margin) and progress on strategic initiatives (Bone Marrow launch, FDA 510(k) process, FPM development). Offsetting risks include APAC weakness (notably China), a distributor inventory adjustment in EMEA that depressed near-term sales, increased working capital leading to a negative total cash flow for the quarter, one-time CEO transition costs (SEK 9m) and temporary operational disruptions (SEK 2m delayed reagents). On balance, the positives — strong regional recovery in the Americas, product/reagent momentum in key markets, continued R&D investment and a solid cash buffer — outweigh the transitory and region-specific headwinds.View all GB:0MR5 earnings summaries0MR5 Stock 12 Month Forecast
Average Price Target
kr150.00
▼(-9.96% Downside)
Technical Analysis
BICO Group AB Class B
―
SciBase Holding AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Acarix AB
―